RxDoctor Payments Data

Andrew Grade, MD

Gastroenterology · Mesa, AZNPI 1881655819

Payments from drug & device makers

$11,225in general payments, 2019–2025

Across 544 payments — averaging $20.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Johnson & Johnson$1K
  • Pfizer$748
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$579
  • Braintree Laboratories, Inc.$487
  • plus $4K from 32 others

What the payments were for

  • Food & beverage$10,51994%
  • Education$2612%
  • Gifts$4464%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,225 in reported general payments places this provider in the 70th percentile of 355 gastroenterology providers in Arizona.

See all gastroenterology providers in Arizona

Medicare billing

Part B allowed, 2024
$390,680
Medicare patients
641
Services billed
11,326

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase42$154,862
OcalivaObeticholic Acid12$110,791
Humira(Cf) PenAdalimumab13$90,454
LinzessLinaclotide65$45,145
XifaxanRifaximin12$37,026
SutabSod Sulf/Pot Chloride/Mag Sulf100$16,415
Colesevelam Hcl71$15,113
Mesalamine37$15,042
Omeprazole670$9,302
MotegrityPrucalopride Succinate17$8,967
Balsalazide Disodium65$8,752
Ursodiol28$7,841
Dexlansoprazole DrDexlansoprazole15$6,514
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates80$5,083
Pantoprazole Sodium304$4,621

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$3,102$200,006107 claims
Intercept Pharmaceuticals, Inc.Ocaliva$228$110,79112 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$579$37,02612 claims
Braintree Laboratories, Inc.Sutab$487$16,415100 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$1,229$8,96717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 355 gastroenterology providers in Arizona.

Other gastroenterology in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →